US Market for Hyaluronic Acid Viscosupplementation 2011-2021; New Report Launched

Viscosupplementation products are approved for direct injection into the knee to relieve pain caused by osteoarthritis. Though the active mechanism is not completely understood, the intention is to restore the shock absorbing nature of the joint fluid.

Although these products treat the symptoms of osteoarthritis and are not permanent cures, patients generally report decreased pain and an improvement in performance of daily activities. Despite the method of application, these products are classified as medical devices and not pharmaceuticals, although some claim that there are associated anti-inflammatory effects.

There are three forms of hyaluronic acid products available on the market: single-injection, three-injection and five-injection cycles. These products vary in their volumes and concentrations of sodium hyaluronate. The three-injection and five-injection products are well-established in the U.S. market. The first single-injection product was approved by the FDA in February 2009; the corresponding market has grown very rapidly.

Spanning over 50 pages, 2 Charts and 2 Figures “US Market for Hyaluronic Acid Viscosupplementation 2011-2021” report covers Research Methodology, Orthopedic Hyaluronic Acid Viscosupplementation Market. This report Covered 6 Companies - Genzyme, Anika Therapeutics, Ferring Pharmaceuticals, Bioventus, Fidia Pharmaceuticals, Zimmer.

For further information on this report, please visit- http://mrr.cm/4EK

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare